Semaglutide/BPC-157 10MG
Conceptual pairing of proven metabolic control (semaglutide) with investigational tissue‑healing support (BPC‑157). Hypothesized benefits include simultaneous weight/metabolic improvements and enhanced soft‑tissue recovery. Evidence for synergy in humans is lacking; safety and interactions are not established.
Semaglutide/BPC-157 Research & Chemical Profile
“Semaglutide / BPC-157” is an informal research pairing that combines a GLP-1 receptor agonist (semaglutide) with the pentadecapeptide BPC-157, which is being investigated for cytoprotective and pro-healing effects. This section summarizes identifiers, rationale for combined exploration, safety considerations, and key references for each constituent.
Chemical Structure / Identifiers — Semaglutide
Property
Detail
Common Name
Semaglutide
Class
GLP-1 receptor agonist (modified human GLP-1 analog)
Sequence
H-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-[γ-Glu-(C18 fatty diacid)])-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Asp-Ser-Ala-Arg-Leu-Gln-Gly-Glu-Arg-Gly-OH
Molecular Formula
C187H291N45O59
Molecular Weight
≈ 4113.58 g/mol
CAS Number
910463-68-2
PubChem CID
56843307
Synonyms
GLP-1 (7-37) analog; Ozempic (brand name); Wegovy (brand name)
Chemical Structure / Identifiers — BPC-157
Property
Detail
Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa)
Molecular Formula
C62H98N16O22
Molecular Weight
≈ 1419.55 g/mol
CAS Number
137525-51-0
PubChem CID
9941957
Synonyms
Body Protection Compound-157; PL 14736; bepecin (research name)
Primary Research Focus (Constituents)
• Semaglutide: Approved GLP-1 receptor agonist for glycemic control and weight management; slows gastric emptying and reduces appetite; ongoing research into cardiovascular and metabolic outcomes.
• BPC-157: Preclinical evidence for gastrointestinal mucosal protection, tendon/ligament healing, angiogenesis support, and anti-inflammatory signaling.Combined Rationale (Research Context)
• Complementary Mechanisms: Semaglutide addresses metabolic pathways, while BPC-157 is reported to support tissue repair and cytoprotection in animal models. The pairing has been hypothesized for research exploring metabolic recovery alongside tissue healing, but this remains speculative.
• Evidence Base: No controlled human trials evaluating the combined use of semaglutide and BPC-157 exist; most literature evaluates each constituent separately.Safety / Limitations
Regulatory Status - Semaglutide is FDA-approved for type 2 diabetes/obesity at specific doses; BPC-157 is not approved for human use by major regulators.
Variability - Semaglutide from unlicensed sources may differ in identity/purity; BPC-157 is typically sold as a research chemical with no standardized manufacturing.
Human Data - Limited or no human data on combined administration; dosing, pharmacokinetics, and long-term safety unknown.
Anti- Doping - Semaglutide is not currently on major anti-doping banned lists, but BPC-157 is prohibited by some sports bodies; confirm current regulations before any laboratory use with athletes.
Key Publications / References
• PubChem Compound Summary: Semaglutide (CID 56843307) https://pubchem.ncbi.nlm.nih.gov/compound/56843307
• Semaglutide clinical review: FDA prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209637s010lbl.pdf
• PubChem Compound Summary: BPC-157 (CID 9941957) https://pubchem.ncbi.nlm.nih.gov/compound/9941957
• Pentadecapeptide BPC-157 enhances tendon outgrowth and fibroblast migration. J Appl Physiol. 2010. PubMed: https://pubmed.ncbi.nlm.nih.gov/21030672/
• Stable gastric pentadecapeptide BPC-157: review of anti-ulcer and systemic cytoprotective effects. World J Gastroenterol. 2015. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC4717094/Disclaimer: For research background only. Not medical advice. “Semaglutide / BPC-157” is an informal concept; combined use has not been validated in human trials.